#OCT is pleased to announce its exclusive Joint Development Agreement with Hypatia AI to develop an AI-enabled asset to scale its drug discovery pipeline. Read more below ⬇ linkedin.com/posts/oxford-c… #OCT #pain #cannabinoids #AI #research

Dr Tim Corn, Chief Medical Officer at Oxford Cannabinoid Technologies discusses the company’s current research into cannabinoid medicines to treat debilitating conditions. OCT’s aim is to develop non-addictive medicines to treat conditions. doceo.tv/o/oxfordcannab…

#OCT is attending #BIOEurope this week in Stockholm, Sweden. We're looking forward to further insightful discussions with partners from across the life science sector. #OCT #cannabinoids #research #drugdiscovery

@OxCanTech inks development deal with ex-Google AI experts, Hypatia AI thepharmaletter.com/oct-inks-devel…

Delighted #OCT’s Finance Director Paul Smalley is representing OCT at this week's Dubai Business Forum -an important event for everyone keen to drive innovation and growth, and help build a value-creating and sustainable future. #DubaiBusinessForum

Proud to have Clarissa Sowemimo-Coker represent #OCT at the BIA Parliament Day reception, engaging with leaders like Steve Bates OBE, Lord Taylor, and Steve Yemm MP. #Innovation #LifeSciences #Leadership #FutureOfHealthcare

Three important milestones for our business as today we become Octavian Therapeutics, announce plans for a fundraise of up to £10M and our Non-Executive Director Lord Mott becomes our Non-Executive Chair. Excited for this next chapter! #OctavianTherapeutics #Research #Biopharma